Termination of a Material Definitive Agreement. Termination of Standby Equity Purchase Agreement On August 31, 2026, MediciNova, Inc. (the “Company”) delivered to YA II PN, LTD. (“Yorkville”), a Notice of Termination, informing Yorkville of the Company’s election to terminate the Standby Equity Purchase Agreement, dated as of July 30, 2025, by and between the Company and Yorkville (the “SEPA”), as required under Section 9.01(b) of the SEPA. Termination of the SEPA will become effective as of…

CEO — Yuichi Iwaki: The filing discloses the execution of new employment agreements for existing executives, which is a compensatory arrangement rather than a change in personnel or management departure.

Results of Operations and Financial Condition. On February 20, 2026 (Japanese Standard Time), MediciNova, Inc. (the “Company”) filed with the Tokyo Stock Exchange a Japanese report referred to as “Kessan Tanshin,” which contained, among other things, the Company’s preliminary, unaudited financial results as of and for the year ended December 31, 2025 (the “Tanshin”). A copy of the English translation of the Tanshin is attached hereto as Exhibit 99.1 and is incorporated by reference herein. Th…

Entry into a Material Definitive Agreement. Equity Distribution Agreement On December 29, 2025, MediciNova, Inc. (the “Company”) entered into an equity distribution agreement with Lucid Capital Markets, LLC (“Agent”) to sell shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), from time to time through the Agent, acting as sales agent, having a maximum aggregate offering price of $50,000,000 (the “Sales Agreement”). Upon delivery of a placement notice and sub…

Entry into a Material Definitive Agreement. On July 30, 2025, MediciNova, Inc. (the “Company”) entered into a Standby Equity Purchase Agreement (the “Purchase Agreement”) with YA II PN, LTD., a Cayman Islands exempt limited company (“Yorkville”). Pursuant to the Purchase Agreement, the Company has the right, but not the obligation, to sell to Yorkville from time to time (each such occurrence, an “Advance”) up to $30.0 million (the “Commitment Amount”) of the Company’s common stock, $0.001 par…

Vice President — Geoffrey O'Brien: Mr. Geoffrey O'Brien is retiring from full-time employment but will continue in a consulting role.

Director — Nicole Lemerond: Ms. Lemerond was appointed as a new director and joined several committees.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 15, 2023, MediciNova, Inc. (the “Company”) received a letter (the “Audit Committee Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, due to Jeff Himawan, Ph.D. not standing for re-election as a Class I director of the Company at the Company’s 2023 annual meeting of stockholders held on June 13, 2023 (the “Annual Meeting”), the Company was no longer in com…

Director — Jeff Himawan, Ph.D.: Dr. Jeff Himawan will not stand for re-election as a Class I director due to health reasons.

Chief Financial Officer — Douglas Paulin: Douglas Paulin resigned as Chief Financial Officer and was replaced by Jason J. Kruger.

Other Events. On March 30, 2022, MediciNova, Inc. was notified that Genzyme Corporation, a subsidiary of Sanofi, filed its First Amended Complaint, which included a claim for infringement of U.S. Patent No. 9,051,542, on February 23, 2022 in a lawsuit previously filed against Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation, and Novartis AG in the U.S. District Court for the District of Delaware. This patent, among others, was included in the Assignment Agreement dated Dece…

Chief Financial Officer — Edward Stepanow: Edward Stepanow resigned as Chief Financial Officer and was replaced by Douglas Paulin.

Entry into a Material Definitive Agreement On July 20, 2021, MediciNova, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with The Irvine Company LLC (the “Landlord”). The Lease is for the Company’s corporate headquarters located at 4275 Executive Square, Suite 300, La Jolla, California, 92037. The term for the Lease is for 60 months, from February 1, 2022 to January 31, 2027. The Lease provides that the Company will pay the Landlord a monthly base rent starting at $14,464.00…